Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer

NCT07403916 | Active Not Recruiting

• 1 other identifier: 129
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease. NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy. The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse. The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management. This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.

Conditions

Gastric Cancer (GC); Next-generation Sequencing; Molecular Analysis

Keywords

Gastric cancer surgery; Next-generation sequencing; Gastric cancer treatment

Outcome Measures

Primary Outcomes (1)

• Overall survival

  3 months

Secondary Outcomes (3)

• Mutational burden and genomic instability features assessed by NGS

  3 months

• Spectrum of somatic mutations identified by NGS

  3 months

• Disease free survival

  3 months

Study Arms (4)

Уoung-adult age group

age 18-44 yr.

Diagnostic Test: Next-generation sequencing

Middle-aged group

age 45-59 yr.

Diagnostic Test: Next-generation sequencing

Eldery age group

age 60-74 yr.

Diagnostic Test: Next-generation sequencing

Senior age group

age \> 75 yr.

Diagnostic Test: Next-generation sequencing

Interventions

Next-generation sequencing DIAGNOSTIC_TEST

Technology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena

Eldery age group; Middle-aged group; Senior age group; Уoung-adult age group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All consecutive patients with clinically documented primary gastric cancer undergoing elective surgery with curative intent

You may qualify if:

• Patients with histologically confirmed diagnosis of gastric cancer
• The resectable stage of the disease (I-III)
• Availability of complete clinical data, including age, gender, stage of the disease, concomitant diseases, treatment tactics and outcomes
• Indicated radical surgical intervention both at the first stage and after neoadjuvant chemotherapy
• Localization of the tumor: Type II-III cardioesophageal junction according to Siewert, upper, middle and lower third of the body, angle of the stomach or antrum (U,M,L-level according to the Japanese classification)

You may not qualify if:

• The presence of metastases in distant organs at the time of diagnosis
• Primary-multiple tumors
• Diagnostic and palliative surgery
• Incomplete clinical data
• Pregnancy

Sponsors & Collaborators

• P. Herzen Moscow Oncology Research Institute: lead

Study Sites (1)

P.Herzen Moscow Oncological Research Institute

Moscow, Russia

Location

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Andrey Ryabov, MD, PhD

  P.Herzen Moscow Oncological Research Institute

  STUDY DIRECTOR

• Vakhtang Begiashvili, PhD student

  P.Herzen Moscow Oncological Research Institute

  PRINCIPAL INVESTIGATOR

• Vladimir Khomyakov, MD, PhD

  P.Herzen Moscow Oncological Research Institute

  PRINCIPAL INVESTIGATOR

• Nadezhda Volchenko, MD, PhD

  P.Herzen Moscow Oncological Research Institute

  PRINCIPAL INVESTIGATOR

• Shatalov Peter, PhD

  P.Herzen Moscow Oncological Research Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PhD student

Study Record Dates

• First Submitted: February 4, 2026
• First Posted: February 11, 2026
• Study Start: January 10, 2020
• Primary Completion: December 31, 2025
• Study Completion: June 1, 2026
• Last Updated: February 11, 2026

Record last verified: 2026-02

Locations

RU (1)